Related Experiment Video

Updated: Jan 18, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.2K

Glycemic Analysis and Stratification of Pediatric Patients with Type 1 Diabetes Using isCGM in Southern Spain:

Isabel Leiva-Gea1,2,3, Fernando Moreno-Jabato2,4, Ana Belén Ariza-Jiménez5,6,7

  • 1Department of Pediatric Endocrinology, Regional University Hospital of Málaga, 29011 Málaga, Spain.

Journal of Clinical Medicine
|September 13, 2025
PubMed

Insights

Few children with type 1 diabetes mellitus (T1D) achieve recommended glucose control targets. Digital platforms like Andiacare can aid management, but improved algorithms are needed for better patient stratification and therapeutic interventions in pediatric diabetes care.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Digital Health

Background:

  • Type 1 diabetes mellitus (T1D) is a prevalent childhood metabolic disorder with significant management challenges.
  • Current insulin therapy and glucometric control are complex, necessitating advanced management strategies.
  • Continuous glucose monitoring (CGM) systems and digital platforms offer new avenues for diabetes care.

Purpose of the Study:

  • To evaluate glucometric control patterns in a pediatric T1D cohort using the Andiacare platform.
  • To analyze the application of an open-source platform for macro/micro-management of pediatric diabetes.
  • To stratify patients based on glucometric control using ATTD panel targets.

Main Methods:

  • Retrospective cohort study of pediatric patients (<18 years) with T1D in Andalusia, Spain.
  • Inclusion of patients using Multiple Daily Injections of Insulin (MDI) and FreeStyle Libre 2 System.
  • Analysis of patient data via the Andiacare platform for glucometric control categorization.

Main Results:

  • 2215 pediatric patients from 18 hospitals were analyzed.
  • Only 25.8% achieved recommended Time in Range (TIR); 9.5% met all glucometric targets.
  • Patient age was a significant factor influencing adherence and goal achievement.

Conclusions:

  • A large proportion of pediatric T1D patients in Andalusia do not meet recommended glucometric control targets.
  • Digital platforms like Andiacare show potential for managing large pediatric cohorts.
  • Development of advanced algorithms integrating diverse parameters is crucial for optimizing T1D management.

Keywords:
advanced technologies and treatments for diabetes (AATD)continuous glucose monitoring (CGM)multiple daily injections of insulin (MDI)pediatric populationtherapeutic scalabilitytime in range (TIR)type 1 diabetes mellitus

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.3K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

721

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.1K